Company has approved financial results for Quarter and year ending 31st March,2026

Revenue Growth 20pctPat Growth 25pctEmphasis Of MatterNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹82.90

prior close

₹82.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+1.9% vs market

Pharmaceuticals peers, median of 162sector-0.5%+1.7% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.1

10m

+0.1

15m

+0.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2-0.6+1.9-0.5+1.7

Next day

+0.1-1.7+1.8-1.2+1.4

-3.4-0.7-2.7-1.5-1.9

+0.0-0.4+0.4-1.6+1.6

-1.2+0.4-1.6-1.1-0.1

+0.1+0.4-0.4-1.3+1.4

-4.6+0.3-4.9-0.7-3.8

15d

-7.1+5.5-12.6+1.3-8.4

-7.1+4.6-11.7+2.6-9.7

-11.3+5.3-16.6+5.3-16.6

-4.4+11.6-15.9+6.9-11.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Drugs Limited reported strong financial performance for FY26. Standalone revenue grew 105% to Rs 7,585 lakhs from Rs 3,693 lakhs, while consolidated revenue increased 74% to Rs 7,874 lakhs from Rs 4,524 lakhs. Profit after tax surged 251% to Rs 103.74 lakhs (standalone) and 214% to Rs 105.50 lakhs (consolidated) compared to the previous year. EPS improved from Rs 0.30 to Rs 0.93 (standalone). However, the auditors flagged that trade receivables of Rs 4.14 crores have been outstanding for over 2 years without any provision for doubtful debts, and cash flow from operations turned negative at Rs 737 lakhs versus positive Rs 316 lakhs in the prior year.

Likely market impact

The company showed exceptional revenue and profit growth, but the auditors' emphasis on long-unpaid receivables and negative operating cash flow raise concerns about collection efficiency and working capital management despite improved profitability.